Name | pristimerin |
Synonyms | pristimerin Celastrol-methylether (9β,13α,14β,20α)-3-Hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oicacidmethylester |
CAS | 1258-84-0 |
Molecular Formula | C30H40O4 |
Molar Mass | 464.64 |
Density | 1.0271 (rough estimate) |
Melting Point | 219.5°C |
Boling Point | 488.1°C (rough estimate) |
Solubility | Soluble in methanol, ethanol, DMSO and other organic solvents |
Appearance | Form Red solid, color orange |
Storage Condition | -20°C |
Refractive Index | 1.4800 (estimate) |
MDL | MFCD01711331 |
Physical and Chemical Properties | Chemical properties red crystal, soluble in methanol, ethanol, DMSO and other organic solvents, derived from Tripterygium wilfordii. |
Use | Use to inhibit cancer cells and ovarian cancer. Used for content determination/identification/pharmacological experiment, etc. |
Toxicity | LD50 oral in mouse: 8gm/kg |
Reference Show more | 1. [IF=5.34] Qun Zhao et al."Pristimerin induces apoptosis and tumor inhibition of oral squamous cell carcinoma through activating ROS-dependent ER stress/Noxa pathway."Phytomedicine. 2021 Nov;92:153723 2. [IF=4.679] Zhuangzhuang Jiang et al."Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells."Food Chem Toxicol. 2021 Jan;147:111919 3. [IF=4.114] Zhao Qun et al."Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo."Cell Death Discov. 2019 Aug;5(1):1-13 4. [IF=2.039] Yingxiang Liu et al."Pristimerin Induces Autophagy‐Mediated Cell Death in K562 Cells through the ROS/JNK Signaling Pathway."Chem Biodivers. 2019 Aug;16(8):e1900325 |
biological activity
Pristimerin is a highly reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 value of 93 nM.
Target
IC50: 93 nM (MGL)
in vitro studies
Pristimerin inhibits the activity of purified MGL with an IC 50 of 93±8 nM and that of non-purified MGL (cell lysates of MGL-transfected HeLa cells) with an IC 50 of 398±68 nM. Pristimerin inhibits MGL through a mechanism that is rapid, reversible and non-competitive. The binding of pristimerin to MGL might be strengthened by formation of a polar interaction with a regulatory cysteine, possibly Cys 208 . Pristimerin inhibits HFLS-RA and HUVEC cell viability in a dose- and time-dependent manner. Pristimerin decreases VEGF-induced autophosphorylation of VEGFR2 and attenuates the activation of the VEGF-induced VEGFR2-mediated signaling pathway .
In vivo studies
Pristimerin inhibits inflammation and tumor angiogenesis. Pristimerin significantly reduces vessel density in synovial membrane tissues of inflamed joints and reduces the expression of pro-angiogenic factors in sera, including TNF-α, Ang-1, and MMP-9.
Solubility | DMSO: ≥5mg/mL |